UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; CDMO; UnicoVial, a cryogenic vial for the storage of cel… Read more
UnicoCell Biomed Co., Ltd. (6794) - Total Assets
Latest total assets as of June 2025: NT$832.20 Million TWD
Based on the latest financial reports, UnicoCell Biomed Co., Ltd. (6794) holds total assets worth NT$832.20 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
UnicoCell Biomed Co., Ltd. - Total Assets Trend (2017–2024)
This chart illustrates how UnicoCell Biomed Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
UnicoCell Biomed Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
UnicoCell Biomed Co., Ltd.'s total assets of NT$832.20 Million consist of 76.2% current assets and 23.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 1.2% |
| Accounts Receivable | NT$8.02 Million | 1.0% |
| Inventory | NT$7.78 Million | 1.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$342.00K | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how UnicoCell Biomed Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: UnicoCell Biomed Co., Ltd.'s current assets represent 76.2% of total assets in 2024, a decrease from 91.4% in 2017.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, down from 86.9% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 1.0% of total assets.
UnicoCell Biomed Co., Ltd. Competitors by Total Assets
Key competitors of UnicoCell Biomed Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
UnicoCell Biomed Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - UnicoCell Biomed Co., Ltd. generates 0.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - UnicoCell Biomed Co., Ltd. is currently not profitable relative to its asset base.
UnicoCell Biomed Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 35.10 | 29.82 | 14.65 |
| Quick Ratio | 34.66 | 29.50 | 14.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$635.91 Million | NT$ 623.05 Million | NT$ 305.01 Million |
UnicoCell Biomed Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between UnicoCell Biomed Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.94 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 13.4% |
| Total Assets | NT$777.89 Million |
| Market Capitalization | $52.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values UnicoCell Biomed Co., Ltd.'s assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: UnicoCell Biomed Co., Ltd.'s assets grew by 13.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for UnicoCell Biomed Co., Ltd. (2017–2024)
The table below shows the annual total assets of UnicoCell Biomed Co., Ltd. from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$777.89 Million | +13.41% |
| 2023-12-31 | NT$685.93 Million | +65.56% |
| 2022-12-31 | NT$414.31 Million | +39.16% |
| 2021-12-31 | NT$297.71 Million | -23.90% |
| 2020-12-31 | NT$391.22 Million | +9.84% |
| 2019-12-31 | NT$356.17 Million | +24.51% |
| 2018-12-31 | NT$286.05 Million | +102.18% |
| 2017-12-31 | NT$141.49 Million | -- |